Stoke Therapeutics (STOK) EBT Margin (2022 - 2026)
Stoke Therapeutics (STOK) posted quarterly EBT Margin of 802.75% for Q1 2026, down 87474.0% year-over-year from N/an in Q1 2025, and up 81.97% quarter-over-quarter from 4453.35% in Q4 2025.
Stoke Therapeutics (STOK) EBT Margin (2022 - 2026) Analysis & Trends
Stoke Therapeutics' EBT Margin history runs 5 years deep, the most recent figure standing at 802.75% for Q1 2026.
- In Q1 2026, EBT Margin fell 87474.0% year-over-year to 802.75%; the TTM figure through Mar 2026 stood at 547.22% (down 57199.0% YoY), while the FY2025 annual figure was 110.77%, up 22276.0% from the prior year.
- EBT Margin for Q1 2026 stood at 802.75%, up from 4453.35% in the prior quarter.
- The five-year high for EBT Margin was 71.99% in Q1 2025, with the low at 5809.03% in Q4 2023.
- The 5-year median for EBT Margin is 802.75% (2026), against an average of 1339.78%.
- The sharpest annual moves came in 2024 and 2025: EBT Margin surged 574384 bps in 2024, then slumped 438816 bps in 2025.
- Stoke Therapeutics' EBT Margin stood at 3811.14% in 2022, then tumbled by 52 bps to 5809.03% in 2023, then soared by 99 bps to 65.19% in 2024, then plunged by 6731 bps to 4453.35% in 2025, then jumped by 82 bps to 802.75% in 2026.
- Business Quant data shows STOK's EBT Margin at 802.75% in Q1 2026, 4453.35% in Q4 2025, and 372.7% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | -660.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -660.78% |
| Mar 31, 2026 | -802.75% |
| Dec 31, 2025 | -4,453.35% |
| Sep 30, 2025 | -372.70% |
| Jun 30, 2025 | -169.96% |
| Mar 31, 2025 | 71.99% |
| Dec 31, 2024 | -65.19% |
| Sep 30, 2024 | -540.05% |
| Jun 30, 2024 | -531.88% |
| Mar 31, 2024 | -625.57% |
| Dec 31, 2023 | -5,809.03% |
| Sep 30, 2023 | -821.46% |
| Jun 30, 2023 | -1,495.04% |
| Mar 31, 2023 | -479.64% |
| Dec 31, 2022 | -3,811.14% |
| Sep 30, 2022 | -1,007.85% |
| Jun 30, 2022 | -996.16% |
| Mar 31, 2022 | -866.50% |